TD-HX206016

Ulocuplumab(TD-HX206016) is a research-grade recombinant antibody targetingCD184. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG4-kappa

Monoclonal

Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolysaccharide-associated protein 3, Leukocyte-derived seven transmembrane domain receptor

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P61073

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

BMS-936564, MDX-1338, MDX1338, 1375830-34-4

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.• CXCR4 (CD184) expression on stem cell harvest and CD34+cells post-transplant., PMID:28282510• CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors., PMID:37375261• CXCR4 in breast cancer: oncogenic role and therapeutic targeting., PMID:26356032• CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies., PMID:34298991• Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina., PMID:27867005• Production of human embryonic kidney 293T cells stably expressing C-X-C chemokine receptor type 4 (CXCR4) as a screening tool for anticancer lead compound targeting CXCR4., PMID:35643380• Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue., PMID:28039356• Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma., PMID:31882334• Development of Mimokines, chemokine N terminus-based CXCR4 inhibitors optimized by phage display and rational design., PMID:29570832• Peptide density targets and impedes triple negative breast cancer metastasis., PMID:29973594

SDS-PAGE for Research Grade Ulocuplumab

For research use only. Not suitable for clinical or therapeutic use.